Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

Mechanism’s Mojo ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

Top Endovascular News of 2023

News Daily News

Top Endovascular News of 2023

December 28, 2023

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

News Daily News

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

August 23, 2022

FDA Approves Lotus Edge, Ushering Third Device Into US Market

News Daily News

FDA Approves Lotus Edge, Ushering Third Device Into US Market

April 24, 2019

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

News Daily News

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

June 05, 2017

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.